Patient and treatment characteristics
| Characteristic . | Entire cohort (N = 1244) . | CHF (n = 88) . | Without CHF (n = 1156) . | P . |
|---|---|---|---|---|
| Female sex, n (%) | 526 (42.3) | 52 (59.1) | 474 (41.0) | < .01 |
| Ethnicity/race, n (%) | ||||
| Non-Hispanic white | 872 (70.0) | 63 (71.6) | 809 (70.0) | .75 |
| Other | 372 (30.0) | 25 (28.4) | 347 (30.0) | |
| Diagnosis, n (%)* | ||||
| Lymphoma | 882 (70.9) | 66 (75.0) | 816 (70.6) | .38 |
| NonHodgkin lymphoma | 598 (48.1) | 47 (53.4) | 551 (47.7) | |
| Hodgkin lymphoma | 284 (22.8) | 19 (21.6) | 265 (22.9) | |
| Nonlymphoma | 362 (29.1) | 22 (25.0) | 340 (29.4) | |
| Acute leukemia | 182 (14.6) | 10 (11.4) | 172 (14.9) | |
| Multiple myeloma | 180 (14.5) | 12 (13.6) | 168 (14.5) | |
| Age at HCT, y | ||||
| Mean (SD) | 43.5 (13.1) | 46.5 (13.1) | 43.3 (13.1) | .03 |
| Range | 5.9-78.9 | 17.2-68.6 | 5.8-78.9 | |
| <35 | 342 (27.5) | 14 (15.9) | 328 (28.4) | .05 |
| 35-44 | 297 (23.9) | 21 (23.9) | 276 (23.9) | |
| 45-54 | 337 (27.1) | 27 (30.7) | 310 (26.8) | |
| ≥55 | 268 (21.5) | 26 (29.5) | 242 (20.9) | |
| Conditioning regimen, n (%) | ||||
| Cyclophosphamide | 1069 (85.9) | 77 (87.5) | 992 (85.8) | .66 |
| Etoposide | 1,031 (82.9) | 73 (83.0) | 958 (82.9) | .98 |
| TBI | 737 (59.2) | 53 (60.2) | 684 (59.2) | .85 |
| Carmustine | 279 (22.4) | 19 (21.6) | 260 (22.5) | .73 |
| Melphalan | 258 (20.7) | 16 (18.2) | 242 (20.9) | .54 |
| Busulfan | 137 (11.0) | 8 (9.1) | 129 (11.2) | .55 |
| Disease status at HCT, n (%) | ||||
| Standard risk | 429 (34.5) | 27 (30.7) | 402 (34.8) | |
| High risk | 754 (65.2) | 61 (69.3) | 754 (65.2) | .44 |
| Subsequent HCT, n (%) | ||||
| No | 1154 (92.8) | 78 (88.6) | 1076 (93.2) | |
| Yes | 90 (7.2) | 10 (11.4) | 80 (6.8) | .12 |
| Characteristic . | Entire cohort (N = 1244) . | CHF (n = 88) . | Without CHF (n = 1156) . | P . |
|---|---|---|---|---|
| Female sex, n (%) | 526 (42.3) | 52 (59.1) | 474 (41.0) | < .01 |
| Ethnicity/race, n (%) | ||||
| Non-Hispanic white | 872 (70.0) | 63 (71.6) | 809 (70.0) | .75 |
| Other | 372 (30.0) | 25 (28.4) | 347 (30.0) | |
| Diagnosis, n (%)* | ||||
| Lymphoma | 882 (70.9) | 66 (75.0) | 816 (70.6) | .38 |
| NonHodgkin lymphoma | 598 (48.1) | 47 (53.4) | 551 (47.7) | |
| Hodgkin lymphoma | 284 (22.8) | 19 (21.6) | 265 (22.9) | |
| Nonlymphoma | 362 (29.1) | 22 (25.0) | 340 (29.4) | |
| Acute leukemia | 182 (14.6) | 10 (11.4) | 172 (14.9) | |
| Multiple myeloma | 180 (14.5) | 12 (13.6) | 168 (14.5) | |
| Age at HCT, y | ||||
| Mean (SD) | 43.5 (13.1) | 46.5 (13.1) | 43.3 (13.1) | .03 |
| Range | 5.9-78.9 | 17.2-68.6 | 5.8-78.9 | |
| <35 | 342 (27.5) | 14 (15.9) | 328 (28.4) | .05 |
| 35-44 | 297 (23.9) | 21 (23.9) | 276 (23.9) | |
| 45-54 | 337 (27.1) | 27 (30.7) | 310 (26.8) | |
| ≥55 | 268 (21.5) | 26 (29.5) | 242 (20.9) | |
| Conditioning regimen, n (%) | ||||
| Cyclophosphamide | 1069 (85.9) | 77 (87.5) | 992 (85.8) | .66 |
| Etoposide | 1,031 (82.9) | 73 (83.0) | 958 (82.9) | .98 |
| TBI | 737 (59.2) | 53 (60.2) | 684 (59.2) | .85 |
| Carmustine | 279 (22.4) | 19 (21.6) | 260 (22.5) | .73 |
| Melphalan | 258 (20.7) | 16 (18.2) | 242 (20.9) | .54 |
| Busulfan | 137 (11.0) | 8 (9.1) | 129 (11.2) | .55 |
| Disease status at HCT, n (%) | ||||
| Standard risk | 429 (34.5) | 27 (30.7) | 402 (34.8) | |
| High risk | 754 (65.2) | 61 (69.3) | 754 (65.2) | .44 |
| Subsequent HCT, n (%) | ||||
| No | 1154 (92.8) | 78 (88.6) | 1076 (93.2) | |
| Yes | 90 (7.2) | 10 (11.4) | 80 (6.8) | .12 |
Analyzed as lymphoma (nonHodgkin lymphoma or Hodgkin lymphoma) versus nonlymphoma (multiple myeloma or acute leukemia).